<DOC>
	<DOC>NCT00925600</DOC>
	<brief_summary>This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation therapy.</brief_summary>
	<brief_title>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Men â‰¥ 30 years of age with nonmetastatic prostate cancer, having undergone bilateral orchiectomy or initiated ADT with GnRH agonists and is expected to continue on ADT for at least 12 months Adequate visual accuracy allowing eye testing Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age; Osteopenia or normal BMD if over 70 years of age Signed informed consent Previous surgery for cataracts in both eyes, current diagnosis of cataracts, cataracts surgery foreseen in the near future, or ocular disease leading to visual loss Diagnosis of osteoporosis</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Lens Opacification</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
	<keyword>Non-metastatic prostate cancer</keyword>
</DOC>